Stage classification and prediction of prognosis: Difference between accountants and speculators

Journal of Thoracic Oncology

Volumn 8, Issue 7, 2013, Pages 820-822

  Detterbeck, Frank ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR;

ADENOCARCINOMA; BIOPSY TECHNIQUE; CANCER PROGNOSIS; CANCER STAGING; COMORBIDITY; GENETIC TRAIT; HUMAN; LUNG CANCER; LUNG SMALL CELL CANCER; NOTE; PREDICTION; PRIORITY JOURNAL;

EID: 84880867642     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318293d98c     Document Type: Note

References (3)

1. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3:75ra26.
2. Groome PA, Bolejack V, Crowley JJ, et al.; IASLC International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (7th) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007;2:694-705.
3. Gospodarowicz M, O'Sullivan B. Prognostic Factors in Cancer Patient Care. In: Gospodarowicz MK, O' Sullivan B, Sobin LH (Eds). Prognostic Factors in Cancer, 2nd Ed. Hoboken, NJ: Wiley-Liss, Inc. pp. 95-104.